{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:05:41Z","timestamp":1790298341846,"version":"4.1.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Walking impairment causes disability and reduced quality of life in patients with multiple sclerosis (MS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Characterize the safety and efficacy of ADS-5102 (amantadine) extended release capsules, 274\u2009mg administered once daily at bedtime in patients with MS with walking impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This randomized, double-blind, placebo-controlled, 4-week study was conducted at 14 trial sites in the United States. Study objectives included safety and tolerability of ADS-5102, and efficacy assessments (Timed 25-Foot Walk (T25FW), Timed Up and Go (TUG), 2-Minute Walk Test, and Multiple Sclerosis Walking Scale-12). Fatigue, depression, and cognition also were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 60 patients were randomized (30 to ADS-5102 and 30 to placebo); 59 of whom were treated. The most frequent adverse events (AEs) were dry mouth, constipation, and insomnia. Five ADS-5102 patients and no placebo patients discontinued treatment due to AEs. One patient in the ADS-5102 group experienced a serious AE\u2014suspected serotonin syndrome. A 16.6% placebo-adjusted improvement was seen in the T25FW test ( p\u2009&lt;\u20090.05). A 10% placebo-adjusted improvement in TUG was also observed. No changes in fatigue, depression, or cognition were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>ADS-5102 was generally well tolerated. These data demonstrate an effect of ADS-5102 on walking speed. Further studies are warranted to confirm these observations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1352458518754716","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T08:27:12Z","timestamp":1516868832000},"page":"601-609","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial"],"prefix":"10.1177","volume":"25","author":[{"given":"Jeffrey A","family":"Cohen","sequence":"first","affiliation":[{"name":"Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel F","family":"Hunter","sequence":"additional","affiliation":[{"name":"Advanced Neuroscience Institute, Franklin, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore R","family":"Brown","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center, Evergreen Health, Kirkland, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gudesblatt","sequence":"additional","affiliation":[{"name":"Comprehensive Multiple Sclerosis Care Center, South Shore Neurologic Associates, P.C., Patchogue, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben W","family":"Thrower","sequence":"additional","affiliation":[{"name":"Crawford Research Institute, Shepherd Center, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Llorens","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc., Emeryville, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy J","family":"Souza-Prien","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc., Emeryville, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April E","family":"Ruby","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc., Emeryville, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N","family":"Chernoff","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc., Emeryville, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Patni","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc., Emeryville, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"key":"bibr1-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000768"},{"key":"bibr2-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000316802.35974.34"},{"key":"bibr3-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182872855"},{"key":"bibr4-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1177\/1352458508088916"},{"key":"bibr5-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60442-6"},{"key":"bibr6-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22240"},{"key":"bibr7-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2013.05.006"},{"key":"bibr8-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100047107"},{"key":"bibr9-1352458518754716","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1017\/S0317167100026603","volume":"14","author":"A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis","year":"1987","journal-title":"Can J Neurol Sci"},{"key":"bibr10-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1989.00520420096030"},{"key":"bibr11-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.11.1956"},{"key":"bibr12-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2003.11.005"},{"key":"bibr13-1352458518754716","first-page":"428","volume":"43","author":"Ashtari F","year":"2009","journal-title":"Neurol Neurochir Pol"},{"key":"bibr14-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2013.09.029"},{"key":"bibr15-1352458518754716","volume-title":"Symmetrel (amantadine hydrochloride, USP) tablets and syrup prescribing information","author":"Endo Laboratories","year":"2009"},{"key":"bibr16-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(70)91211-0"},{"key":"bibr17-1352458518754716","volume-title":"GOCOVRI\u2122 (amantadine) extended release capsules (prescribing information)","year":"2017"},{"key":"bibr18-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26159"},{"key":"bibr19-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27131"},{"key":"bibr20-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0943"},{"key":"bibr21-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067357"},{"issue":"11","key":"bibr22-1352458518754716","first-page":"433","volume":"21","author":"Nguyen J","year":"2015","journal-title":"Mult Scler J"},{"key":"bibr23-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22366"},{"key":"bibr24-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"bibr25-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517690823"},{"key":"bibr26-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2004.02.010"},{"key":"bibr27-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.284.6329.1607"},{"key":"bibr28-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.60.1.31"},{"key":"bibr29-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509348519"},{"key":"bibr30-1352458518754716","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1996.79.3.929"},{"key":"bibr31-1352458518754716","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-55"},{"key":"bibr32-1352458518754716","doi-asserted-by":"crossref","unstructured":"Hobart J, Ziemssen T, Feys P, et al. Prolonged-release fampridine induces sustained clinically meaningful improvements in walking ability in people with multiple sclerosis: Results from the ENHANCE trial (P6.364). Neurology 2017; 88. (16 Supplement), http:\/\/n.neurology.org\/content\/88\/16_Supplement\/P6.364 (accessed 12 January 2018).","DOI":"10.1212\/WNL.88.16_supplement.P6.364"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458518754716","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1352458518754716","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458518754716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:53:49Z","timestamp":1777694029000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458518754716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,25]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1177\/1352458518754716"],"URL":"https:\/\/doi.org\/10.1177\/1352458518754716","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732570091.793559737","asserted-by":"object"}]},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,25]]}}}